Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Boosted by Bridgewater Associates LP

Bridgewater Associates LP boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 122.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 460,936 shares of the biopharmaceutical company's stock after purchasing an additional 253,994 shares during the period. Bridgewater Associates LP's holdings in Gilead Sciences were worth $42,577,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Westside Investment Management Inc. grew its position in shares of Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock worth $2,249,000 after buying an additional 917 shares in the last quarter. SkyView Investment Advisors LLC raised its stake in Gilead Sciences by 5.4% in the third quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 435 shares in the last quarter. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $209,000. World Investment Advisors LLC increased its holdings in shares of Gilead Sciences by 33.6% in the 3rd quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock valued at $2,180,000 after acquiring an additional 6,535 shares during the last quarter. Finally, Arvest Bank Trust Division purchased a new stake in Gilead Sciences during the third quarter worth approximately $9,661,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Oppenheimer upped their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Stock Down 0.4 %

NASDAQ:GILD traded down $0.39 during mid-day trading on Friday, reaching $104.49. The stock had a trading volume of 8,066,368 shares, compared to its average volume of 7,515,503. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market capitalization of $130.10 billion, a price-to-earnings ratio of 282.40, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock's 50 day simple moving average is $108.99 and its two-hundred day simple moving average is $97.30.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.02%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $19,977,938.37. This represents a 9.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 302,785 shares of company stock worth $30,540,875. Insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.